Please check your internet connection and try again.
### Mycoplasma (Pathogen, Not a Drug)
**Overview**
*Mycoplasma* is a genus of bacteria that lack a cell wall. Several species are pathogenic in humans, most notably *Mycoplasma pneumoniae*, a common cause of atypical pneumonia. Treatment focuses on eradicating the specific *Mycoplasma* species identified.
**Primary Indications**
* Infections caused by *Mycoplasma* species, including:
* Atypical pneumonia (*Mycoplasma pneumoniae*)
* Genitourinary infections (*Mycoplasma genitalium*, *Ureaplasma urealyticum*)
**Adult Dosing**
The choice of antibiotic and duration of therapy depends on the specific *Mycoplasma* species and the site of infection. Common antibiotic classes used include macrolides, tetracyclines, and fluoroquinolones.
* **For *Mycoplasma pneumoniae* (e.g., community-acquired pneumonia):**
* **Azithromycin:** 500 mg on day 1, then 250 mg once daily for 4 days (total 5 days).
* **Clarithromycin:** 500 mg twice daily for 7-14 days.
* **Doxycycline:** 100 mg twice daily for 7-14 days.
* **Levofloxacin:** 500 mg once daily for 7-14 days.
* **Moxifloxacin:** 400 mg once daily for 7-14 days.
* **For *Mycoplasma genitalium*:**
* **Azithromycin:** 1 g once daily for 3 days (alternative regimen for suspected macrolide-susceptible infections). This regimen has a *higher failure rate* for urogenital infections compared to other options.
* **Moxifloxacin:** 400 mg once daily for 7 days (preferred regimen for suspected macrolide-resistant infections).
* **Doxycycline:** 100 mg twice daily for 14 days (often used in combination with azithromycin for suspected macrolide-susceptible infections).
* **For *Ureaplasma urealyticum*:**
* **Doxycycline:** 100 mg twice daily for 14 days.
* **Azithromycin:** 1 g once on day 1, then 500 mg once daily for 4 days.
**Pediatric Dosing**
Dosing for pediatric patients depends on age, weight, and specific pathogen. Local guidelines and specialist consultation are recommended.
* **For *Mycoplasma pneumoniae* in children > 6 months:**
* **Azithromycin:** 10 mg/kg on day 1 (max 500 mg), then 5 mg/kg once daily for 4 days (max 250 mg/day). Total 5 days.
* **Clarithromycin:** 7.5 mg/kg twice daily (max 500 mg/dose) for 7-14 days.
**Dose Adjustments**
Dose adjustments are typically based on the chosen antibiotic's pharmacokinetic profile and the presence of hepatic or renal impairment, not directly for the *Mycoplasma* infection itself. Refer to specific antibiotic prescribing information.
**Contraindications**
Contraindications are specific to the chosen antibiotic agent, not *Mycoplasma* itself. For example, macrolides are contraindicated in patients with known hypersensitivity. Fluoroquinolones carry a risk of tendon rupture and should be used cautiously in children and adolescents.
**Adverse Effects**
Adverse effects are specific to the chosen antibiotic agent.
* **Macrolides (e.g., Azithromycin, Clarithromycin):** Gastrointestinal upset (diarrhea, nausea, abdominal pain), QT interval prolongation.
* **Tetracyclines (e.g., Doxycycline):** Photosensitivity, gastrointestinal upset, tooth discoloration in children < 8 years, esophageal irritation.
* **Fluoroquinolones (e.g., Levofloxacin, Moxifloxacin):** Tendonitis and tendon rupture, CNS effects (dizziness, confusion), QT interval prolongation, peripheral neuropathy.
**Key Drug Interactions**
Drug interactions are specific to the chosen antibiotic agent.
* **Macrolides:** CYP3A4 inhibitors (increase levels of certain drugs like warfarin, digoxin).
* **Tetracyclines:** Antacids, calcium, iron, magnesium, zinc can decrease absorption. Avoid concurrent administration.
* **Fluoroquinolones:** Antacids, iron, calcium, magnesium, zinc can decrease absorption. Warfarin (increased INR).
**Monitoring**
* Clinical response to treatment (resolution of symptoms).
* Adverse effects related to the chosen antibiotic.
* For *Mycoplasma genitalium*, test-of-cure after treatment is recommended, especially following regimens with higher failure rates or if symptoms persist.
**Clinical Pearls**
* *Mycoplasma pneumoniae* is a common cause of walking pneumonia and may require prolonged treatment.
* Antibiotic resistance, particularly to macrolides for *Mycoplasma genitalium*, is a significant concern. Susceptibility testing or empirical use of fluoroquinolones may be warranted in certain clinical scenarios.
* The absence of a cell wall means *Mycoplasma* are intrinsically resistant to beta-lactam antibiotics (e.g., penicillins, cephalosporins).
* Diagnosis can be challenging; molecular methods are often preferred for accurate identification.
***
**Disclaimer:** This information is for educational purposes only and does not substitute for professional medical advice. Always consult with a qualified healthcare provider and refer to the most current prescribing information and guidelines before making any treatment decisions. Dosing and treatment protocols may vary based on local guidelines and individual patient factors.
